MedTrace Logo

To Evaluate SSD8432/Ritonavir in Adults With COVID-19

NCT05373433 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 670

Last updated 2022-05-24

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled, phase II/III clinical study to evaluate the efficacy and safety of SSD8432 in combination with ritonavir in adult subjects with mild/common COVID-19.

Conditions

Interventions

DRUG

SSD8432 750mg

Experimental group:SSD8432 750mg and Ritonavir 100mg, Day1--Day5,BID

DRUG

SSD8432 placebo

Control group :SSD8432 placebo and Ritonavir placebo, Day1--Day5,BID

Sponsors & Collaborators

  • Jiangsu Simcere Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yumei Yang, Doctor · Jiangsu Xiansheng Pharmaceutical Co.,

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-26
Primary Completion
2023-05-31
Completion
2023-10-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05373433 on ClinicalTrials.gov